Afatinib (Giotrif®) : The 1st choice in 1st-line

Afatinib: The 1st line choice in sequential therapy of NSCLC

 
 

AFATINIB significantly reduces the relative risk in disease progression or death vs gefitinib in NSCLC

Document ID: PC-VN-101465

28/06/2021

Author: Boehringer Ingelheim

123,000
Views

100k 340

NHỮNG NỘI DUNG LIÊN QUAN

 
PC-VN-101465
Production date: June 2021